Abbott Soars into Q1 2026 with Strong Earnings and Strategic Milestones
Abbott, a leading global healthcare company, has reported strong first-quarter (Q1) 2026 earnings and achieved several strategic milestones in its medical device business. The company's adjusted earnings per share came in at $1.15, meeting its guidance despite absorbing the impact of earlier-than-planned financing costs related to the acquisition of Exact Sciences and a weaker-than-expected respiratory season.
"Our results in the first quarter were aligned with our expectations for the start of the year," said Robert Ford, Chairman and Chief Executive Officer of Abbott. "This included delivering adjusted earnings per share of $1.15, consistent with our guidance, despite absorbing the impact of earlier-than-planned financing costs related to our acquisition of Exact Sciences and a weaker-than-expected respiratory season."
The company's Q1 2026 earnings call was highlighted by several notable achievements in its medical device business. These included an earlier-than-planned approval and launch of two new PFA catheters, completion of patient enrollment in the CATALYST left atrial appendage device trial, initiation of development activities to bring an implantable extravascular ICD product to market, and positive results from a randomized controlled trial demonstrating the benefits of using Libre for people with type 2 diabetes on basal insulin therapy.
"We're excited about the progress we've made in our medical device business," said Robert Ford. "These achievements demonstrate our commitment to innovation and our ability to bring new technologies to market."
The acquisition of Exact Sciences, a cancer diagnostics company, marked an important strategic milestone for Abbott. The addition of Exact Sciences is expected to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate.
"This acquisition adds a new high-growth business to the Abbott portfolio, further strengthening our leadership position in diagnostics and expanding our presence into one of the fastest-growing areas of healthcare, cancer diagnostics," said Robert Ford.
Abbott's pipeline achievements and strategic milestones are expected to drive growth and innovation in its medical device business. The company is preparing to initiate patient enrollment in several important clinical trials in the second half of this year, which represent a unique opportunity to bring new highly differentiated technologies to the market.
